CRYOPDP is the first choice courier for the Life Sciences and Healthcare industries with more than 25 years of experience, which has a mission to improve the health of people around the world. Headquartered in Paris, France, CRYOPDP provides turnkey premium temperature-controlled logistics solutions to the Clinical Research, Pharmaceutical, and Cell and Gene Therapy markets.
The company covers a significant portion of the healthcare temperature-controlled supply chain, including premium services, packaging, pick-pack kit preparation, specialty courier support, and premium added value solutions such as Lab Move, Direct-to-Patient, and Control Tower, a fully integrated project management solution.
The Cellex group offers a broad spectrum of services in pharma, biotech, clinical and research institutions in the field of cellular therapies for clinical and commercial use. Our company has experience in GMP manufacturing of autologous and allogeneic cell types, for instance for CAR-T technologies, which are genetically modified with retroviral and lentiviral vectors. Our apheresis centers have all techniques for collection of different cell products from healthy donors for clinical use, research or commercial purpose; moreover autologous collections can be performed. Cellex runs its own data base “CellCommunity” with many different types of donors willing to support research. Our state-of-the art Cellex Cell Manufacturing Plant, based in Cologne, offers GMP-compliant contract ATMP manufacturing. Cellular subsets are separated, genetically modified, analyzed and frozen. In addition, we also take care of fast and safe transports – as cargo or with courier on board – to worldwide destinations. Cellex also offers development activities either as continuous process improvement, or on a contract basis for customers in order to meet their specific needs on a high professional level.
BIA Separations, now a Sartorius company, develops and manufactures market-leading CIM® monolithic chromatographic columns for purification and analysis of large biomolecules, such as viruses, plasmids and mRNA, which are applied in cell and gene therapies. BIA’s Cornerstone® Biomanufacturing Development Services are result of more than 20 year of hands-on experience with the most challenging biopharmaceutical products and offer a comprehensive approach of integrated process development solutions and novel technology designed to improve the robustness and yield of large biomolecules production, while improving the safety of therapeutic products. BIA's technology for manufacturing-scale purification is already used in production of the first commercialized advanced therapeutics; BIA also has a keen presence with novel drug candidates in the clinical pipeline.